CoChat

Ulipristal Acetate Prior to Surgery for Endometriosis

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Selective progesterone receptor modulators may have a role in the treatment of endometriosis. The aim of this report is to review the effect of ulipristal acetate (UPA) on endometriosis lesions and symptoms in women treated prior to surgery. A pathology review of eutopic endometrium and endometriotic lesions was conducted by two gynecologic pathologists. The main outcome measures reported are pain reduction, amenorrhea, and pathologic progesterone receptor modulator-associated endometrial changes (PAECs). Overall, fifteen women with endometriosis received UPA over a 27-month study period. UPA was administered in an intermittent fashion in the majority of patients while 27% of patients had continuous treatment, between 6 and 24 months. Eleven (73%) patients reported amenorrhea on UPA and 11 (92%) of 12 patients with pain reported pain reduction or resolution. Fourteen patients (93%) proceeded with surgical management. Thirteen (93%) patients underwent excision of suspected endometriosis at surgery. Twelve cases (86%) had concurrent eutopic endometrium specimens and PAEC was identified in 58% (n = 7). Among the 14 cases that underwent surgery, a total of 49 extraovarian sites were sampled. Endometriosis was definitively identified in 31 (63%) of these sites. Three cases (21%) showed morphologic features similar to PAEC within foci of endometriosis. All cases of PAEC-like features in endometriosis also had PAEC in the endometrium. These patients had all noted pain reduction and amenorrhea preoperatively. In conclusion, PAECs may be found in endometriosis lesions in patients treated with UPA. Further prospective investigation is required to evaluate the efficacy and safety of SPRMs in women with endometriosis.

Overview

Integrity signals

Registry

Crossref · 10.1007/s43032-020-00146-1

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 16 references

Research works printed but not linked: 2

  1. Bulun S. Ulipristal acetate for treatment of endometriosis-related pelvic pain. [Phase IV clinical trial]. In press Active.
  2. Bayer. Assess safety and efficacy of vilaprisan in subjects with endometriosis (VILLENDO). [Phase II clinical trial]. In press Active.

Cited by

See all 10

Metadata

Authors
Singh, S. S., Evans, D., McDonald, S., Senterman, M., & Strickland, S.
Affiliations
  • University of Ottawa (CA)
  • University of Manitoba (CA)
Corresponding author
Singh, Sukhbir S.
Venue
Reproductive Sciences
Published
2020-01-31
Volume
27
Issue
9
Pages
1707-1714
ISSN
  • 1933-7191 (ISSN-L)
  • 1933-7205
OpenAlex
W3006040240
Cited by
10
References
16
Citations by year
2025: 1 · 2024: 1 · 2023: 2 · 2022: 5 · 2021: 1
FWCI
1.77
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Reproductive Sciences (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
Keywords
ulipristal acetate, endometriosis, selective progesterone receptor modulators, preoperative treatment, eutopic endometrium, endometriosis excision, dysmenorrhea, amenorrhea
MeSH terms
Contraceptive Agents, Hormonal, Adult, Combined Modality Therapy, Endometriosis, Endometrium, Female, Humans, Middle Aged, Norpregnadienes, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ulipristal Acetate Prior to Surgery for Endometriosis. https://app.cochat.ai/papers/10.1007/s43032-020-00146-1
The paper
Singh, S. S., Evans, D., McDonald, S., Senterman, M., & Strickland, S. (2020). Ulipristal Acetate Prior to Surgery for Endometriosis. Reproductive Sciences. https://doi.org/10.1007/s43032-020-00146-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.